{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:56:03Z","timestamp":1789541763524,"version":"build-2803163510"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Using clinically relevant animal models, we have recently demonstrated that the anticonvulsant primidone (Liskantin<jats:sup>\u00ae<\/jats:sup>), approved by the FDA for the treatment of various forms of epilepsy, can effectively block RIPK1 enzymatic activity, which mediates cell death, and consequently prevent RIPK1 cytotoxicity and associated inflammatory responses. Based on these findings, we now reveal both a preventive and, more importantly, a therapeutic effect of primidone in the imiquimod (IMQ)-induced psoriasis-like inflammation model. Notably, the protective effect of IMQ in this necroinflammatory disease is directly correlated with inhibition of the activated state of RIPK1 (as monitored by auto-phosphorylation on Ser166\/T169), a critical marker that had been missing in the highly contradictory studies that have previously been published. This allows us to unequivocally identify RIPK1 as a therapeutic target in the treatment of inflammatory disorders, including psoriasis. Given that newly developed RIPK1 inhibitors have shown very limited success in clinical trials for inflammatory and neurological diseases in recent years, and that none of these inhibitors has yet reached clinical utilization, our data strongly recommend a clinical study to evaluate the already approved drug primidone for the treatment of patients suffering from psoriasis within the context of drug repurposing.<\/jats:p>","DOI":"10.1038\/s41420-025-02552-3","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T19:53:20Z","timestamp":1749585200000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Primidone: a clinically promising candidate for the treatment of psoriasis"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9084-3826","authenticated-orcid":false,"given":"Theresa","family":"Riebeling","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6331-8388","authenticated-orcid":false,"given":"Benedikt","family":"Kolbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Philippsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Dahlke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Delanghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8810-4717","authenticated-orcid":false,"given":"Franziska","family":"Theilig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agatha","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4415-8355","authenticated-orcid":false,"given":"Roland","family":"Schmitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu J. M.","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Kunzendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7768-2132","authenticated-orcid":false,"given":"Stefan","family":"Krautwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"2552_CR1","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945\u201360.","journal-title":"JAMA"},{"key":"2552_CR2","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1038\/s41418-018-0232-2","volume":"26","author":"C Moerke","year":"2019","unstructured":"Moerke C, Jaco I, Dewitz C, M\u00fcller T, Jacobsen AV, Gautheron J, et al. The anticonvulsive Phenhydan\u00ae suppresses extrinsic cell death. Cell Death Differ. 2019;26:1631\u201345.","journal-title":"Cell Death Differ"},{"key":"2552_CR3","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1038\/s41418-020-00690-y","volume":"28","author":"T Riebeling","year":"2021","unstructured":"Riebeling T, Jamal K, Wilson R, Kolbrink B, von Samson-Himmelstjerna FA, Moerke C, et al. Primidone blocks RIPK1-driven cell death and inflammation. Cell Death Differ. 2021;28:1610\u201326.","journal-title":"Cell Death Differ"},{"key":"2552_CR4","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41573-020-0071-y","volume":"19","author":"L Mifflin","year":"2020","unstructured":"Mifflin L, Ofengeim D, Yuan J. Receptor-interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov. 2020;19:553\u201371.","journal-title":"Nat Rev Drug Discov"},{"key":"2552_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41580-023-00689-6","volume":"25","author":"J Yuan","year":"2024","unstructured":"Yuan J, Ofengeim D. A guide to cell death pathways. Nat Rev Mol Cell Biol. 2024;25:379\u201395.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2552_CR6","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jdermsci.2018.04.007","volume":"91","author":"N Saito","year":"2018","unstructured":"Saito N, Honma M, Shibuya T, Iinuma S, Igawa S, Kishibe M, et al. RIPK1 downregulation in keratinocyte enhances TRAIL signaling in psoriasis. J Dermatol Sci. 2018;91:79\u201386.","journal-title":"J Dermatol Sci"},{"key":"2552_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2328-0","volume":"11","author":"X Duan","year":"2020","unstructured":"Duan X, Liu X, Liu N, Huang Y, Jin Z, Zhang S, et al. Inhibition of keratinocyte necroptosis mediated by RIPK1\/RIPK3\/MLKL provides a protective effect against psoriatic inflammation. Cell Death Dis. 2020;11:134.","journal-title":"Cell Death Dis"},{"key":"2552_CR8","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13857","volume":"17","author":"ALA Sun","year":"2024","unstructured":"Sun ALA, Gillies JD, Shen Y, Deng H, Xue F, Ma Y, et al. A phase I randomized study to evaluate safety, pharmacokinetics, and pharmacodynamics of SIR2446M, a selective RIPK1 inhibitor, in healthy participants. Clin Transl Sci. 2024;17:e13857.","journal-title":"Clin Transl Sci"},{"key":"2552_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116123","volume":"265","author":"Y Bai","year":"2024","unstructured":"Bai Y, Qiao Y, Li M, Yang W, Chen H, Wu Y, et al. RIPK1 inhibitors: a key to unlocking the potential of necroptosis in drug development. Eur J Med Chem. 2024;265:116123.","journal-title":"Eur J Med Chem"},{"key":"2552_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s13555-024-01097-0","volume":"14","author":"VJ Ludbrook","year":"2024","unstructured":"Ludbrook VJ, Budd DC, Thorn K, Tompson D, Votta BJ, Walker L, et al. Inhibition of receptor-interacting protein kinase 1 in chronic plaque psoriasis: a multicenter, randomized, double-blind, placebo-controlled study. Dermatol Ther. 2024;14:489\u2013504.","journal-title":"Dermatol Ther"},{"key":"2552_CR11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jid.2020.04.031","volume":"141","author":"A Schwarz","year":"2021","unstructured":"Schwarz A, Philippsen R, Schwarz T. Induction of regulatory T cells and correction of cytokine disbalance by short-chain fatty acids: implications for psoriasis therapy. J Invest Dermatol. 2021;141:95\u2013104.","journal-title":"J Invest Dermatol"},{"key":"2552_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-021-03994-0","volume":"12","author":"T Delanghe","year":"2021","unstructured":"Delanghe T, Huyghe J, Lee S, Priem D, van Coillie S, Gilbert B, et al. Antioxidant and food additive BHA prevents TNF cytotoxicity by acting as a direct RIPK1 inhibitor. Cell Death Dis. 2021;12:699.","journal-title":"Cell Death Dis"},{"key":"2552_CR13","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1016\/j.jid.2022.05.1083","volume":"142","author":"M Bruno","year":"2022","unstructured":"Bruno M, Davidson L, Koenen H, van den Reek JMPA, van Cranenbroek B, de Jong EMGJ, et al. Immunological effects of anti-IL-17\/12\/23 therapy in patients with psoriasis complicated by candida infections. J Invest Dermatol. 2022;142:2929\u201339.","journal-title":"J Invest Dermatol"},{"key":"2552_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113388","volume":"143","author":"F Ferrara","year":"2024","unstructured":"Ferrara F, Verduci C, Laconi E, Mangione A, Dondi C, del Vecchio M, et al. Current therapeutic overview and future perspectives regarding the treatment of psoriasis. Int Immunopharmacol. 2024;143:113388.","journal-title":"Int Immunopharmacol"},{"key":"2552_CR15","doi-asserted-by":"publisher","first-page":"6367","DOI":"10.1073\/pnas.86.16.6367","volume":"86","author":"RM Grossman","year":"1989","unstructured":"Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, May LT, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA. 1989;86:6367\u201371.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2552_CR16","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/s12276-021-00620-z","volume":"53","author":"L Hao","year":"2021","unstructured":"Hao L, Mao Y, Park J, Kwon BM, Bae EU, Park BH. 2\u2019-Hydroxycinnamaldehyde ameliorates imiquimod-induced psoriasiform inflammation by targeting PKM2-STAT3 signaling in mice. Exp Mol Med. 2021;53:875\u201384.","journal-title":"Exp Mol Med"},{"key":"2552_CR17","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.jid.2022.01.014","volume":"142","author":"PC van de Kerkhof","year":"2022","unstructured":"van de Kerkhof PC. From empirical to pathogenesis-based treatments for psoriasis. J Invest Dermatol. 2022;142:1778\u201385.","journal-title":"J Invest Dermatol"},{"key":"2552_CR18","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41581-022-00658-w","volume":"19","author":"B Kolbrink","year":"2023","unstructured":"Kolbrink B, von Samson-Himmelstjerna FA, Murphy JM, Krautwald S. Role of necroptosis in kidney health and disease. Nat Rev Nephrol. 2023;19:300\u201314.","journal-title":"Nat Rev Nephrol"},{"key":"2552_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113626","volume":"144","author":"SJ Kshirsagar","year":"2025","unstructured":"Kshirsagar SJ, Adhav PS, Laddha UD, Ganore JS, Pagar CS, Bambal VR. Navigating psoriasis: from immune mechanisms to natural healing approaches. Int Immunopharmacol. 2025;144:113626.","journal-title":"Int Immunopharmacol"},{"key":"2552_CR20","first-page":"6665","volume":"8","author":"Y Wang","year":"2015","unstructured":"Wang Y, Zhao J, Zhang L, Di T, Liu X, Lin Y, et al. Suppressive effect of \u03b2, \u03b2-dimethylacryloyl alkannin on activated dendritic cells in an imiquimod-induced psoriasis mouse model. Int J Clin Exp Pathol. 2015;8:6665\u201373.","journal-title":"Int J Clin Exp Pathol"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02552-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02552-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02552-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T19:53:21Z","timestamp":1749585201000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-025-02552-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2552"],"URL":"https:\/\/doi.org\/10.1038\/s41420-025-02552-3","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal care and experimental procedures were conducted in accordance with the animal protection regulations of the local authorities and have been approved by the Ministry of Agriculture, Rural Areas, European Affairs and Consumer Protection of Schleswig-Holstein, Germany [AZ: V242-29444\/2019 (59-5\/19)].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"275"}}